This study is about testing a new drug called obeldesivir (ODV), also known as GS-5245, for adults with acute respiratory syncytial virus (RSV) infection. RSV is a virus that causes lung and breathing problems. The study will check if ODV helps people feel better faster and if it is safe to use.

To be part of the study, you need to be at least 60 years old or have certain lung or heart diseases. Your RSV infection needs to have been confirmed within the last 3 days, and you should not have had an RSV vaccine if your only risk factor is age. You cannot join if you need hospital care soon, have other infections like COVID-19, or if you are pregnant.

• The study involves taking ODV to see its effects on your symptoms.
• You must not have taken other specific antiviral treatments recently.
• There may be additional criteria to consider before joining the study.